News headlines about DBV Technologies (NASDAQ:DBVT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DBV Technologies earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.450840972194 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of equities analysts have recently weighed in on DBVT shares. ValuEngine cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a research report on Tuesday, October 24th. BidaskClub lowered shares of DBV Technologies from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of DBV Technologies in a research note on Monday, October 23rd. Finally, JMP Securities initiated coverage on shares of DBV Technologies in a research note on Friday, November 17th. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. DBV Technologies currently has a consensus rating of “Buy” and an average target price of $49.63.
Shares of DBV Technologies (NASDAQ:DBVT) opened at $26.29 on Friday. DBV Technologies has a twelve month low of $20.58 and a twelve month high of $50.57.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/01/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-dbv-technologies-dbvt-share-price.html.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.